| CARDIFF ONCOLOGY |
| USA |
| Gesundheit |
| US14147L1089 / A2P4GU |
| XE7C (Frankfurt) / CRDF (NASDAQ) |
| FRA:XE7C, ETR:XE7C, XE7C:GR, NASDAQ:CRDF |
| - |
| https://cardiffoncology.c.. |
|
Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for cancers with significant unmet needs. Its lead candidate, onvansertib, is an oral, selective polo-like kinase 1 (PLK1) i..
>Volltext.. |
| 82.24 Mio. EUR |
| 43.03 Mio. EUR |
| 0.45 Mio. EUR |
| -39.98 Mio. EUR |
| -38.46 Mio. EUR |
| -0.57 EUR |
| 0.56 Mio. EUR |
| 7.34 Mio. EUR |
| - |
| 3.18 |
| -16.4% |
| 14.21% |
| - |
| - |
| - |
| - |
| CARDIFF ONCOLOGY |
| 05.06.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|